drugset / Trial / NCT05124483
Anti-COVID19 VaccinaTion AKS-452 BOOSTER (ACT-BOOSTER Study)
Phase 2
Unknown
600 enrolled
University Medical Center Groningen
PRA Health Sciences · collabTRACER Europe BV · collab
Non-randomizedSingle-groupOpen-labelOther
Summary
Aim: To investigate if a subcutaneous (s.c.) booster dose of 90 µg of the naked Akston AKS-452 vaccine (AKS-452X) at \>= 3 months post initial vaccination, with any of the four registered vaccines, will boost the antibody titer and immune response in human healthy volunteers 4-6 weeks after s.c. injection.
Timeline
- Start
- 2022-04-21
- Primary completion
- 2022-07-01
- Completion
- 2023-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AKS-452X | Vaccine | 90 ug | Subcutaneous |